ABO2013 + sintilimab

ABO2013 + sintilimab is an investigational combination therapy composed of two agents:

• ABO2013 (details on this agent are not available in the provided sources or major drug databases; it is likely a code name for an experimental compound, possibly developed by a Chinese pharmaceutical company).
• Sintilimab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor. Sintilimab blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell mediated immune responses against tumor cells. It has been primarily investigated for use in various cancers, including non-small cell lung cancer (NSCLC). Sintilimab was co-developed by Innovent Biologics and Eli Lilly and Company.

The combination of ABO2013 with sintilimab suggests a strategy to enhance antitumor efficacy through dual mechanisms—though the specific mechanism of ABO2013 cannot be confirmed from available data.